Evidence map›Paper›PMID 29132323›Full record

ArticleBMC cancer2017

Integrative microRNA and mRNA deep-sequencing expression profiling in endemic Burkitt lymphoma.

Cliff I Oduor, Yasin Kaymaz, Kiprotich Chelimo, Juliana A Otieno, John Michael Ong'echa, Ann M Moormann, Jeffrey A Bailey

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 28 citations in OpenAlex.

  1. miRNA profiling in pediatric and young adult Burkitt leukemia and lymphoma.Virchows Archiv : an international journal of pathology · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. MiRNA Dysregulation in Childhood Hematological Cancer.International journal of molecular sciences · 2018
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Cliff I OduorCenter for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya.
Yasin KaymazDepartment of Bioinformatics & Integrative Biology, University of Massachusetts Medical School, Worcester, MA, USA.
Kiprotich ChelimoDepartment of Biomedical Sciences and Technology, Maseno University, Maseno, Kenya.
Juliana A OtienoJaramogi Oginga Odinga Teaching and Referral Hospital, Ministry of Health, Kisumu, Kenya.
John Michael Ong'echaCenter for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya.
Ann M MoormannDepartment of Molecular Medicine, University of Massachusetts Medical School, Worcester, MA, USA.
Jeffrey A BaileyDepartment of Bioinformatics & Integrative Biology, University of Massachusetts Medical School, Worcester, MA, USA. jeffrey.bailey@umassmed.edu.
University of Massachusetts Chan Medical School · USKenya Medical Research Institute · KEMaseno University · KEMinistry of Health · KE

Funding

University of Massachusetts Center for Clinical and Translational ScienceUL1TR000161 · NCATS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI LUZURIAGA, KATHERINE F · 2012 to 2015
$11.0M
Impact of malaria on shaping immunity to EBV in the etiology of Burkitt lymphomaR01CA189806 · NCI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI MOORMANN, ANN M · 2014 to 2024
$5.7M
T Cell Immunity in Endemic Burkitt LymphomaR01CA134051 · NCI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI MOORMANN, ANN M · 2008 to 2012
$2.3M
NCATS NIH HHS UL1 TR000161NCI NIH HHS R01 CA134051NCI NIH HHS R01CA134051NCI NIH HHS R01 CA189806NCI NIH HHS R01CA189806
6 · The paper itself

Abstract

backgroundBurkitt lymphoma (BL) is characterized by overexpression of the c-myc oncogene, which in the vast majority of cases is a consequence of an IGH/MYC translocation. While myc is the seminal event, BL is a complex amalgam of genetic and epigenetic changes causing dysregulation of both coding and non-coding transcripts. Emerging evidence suggest that abnormal modulation of mRNA transcription via miRNAs might be a significant factor in lymphomagenesis. However, the alterations in these miRNAs and their correlations to their putative mRNA targets have not been extensively studied relative to normal germinal center (GC) B cells.

methodsUsing more sensitive and specific transcriptome deep sequencing, we compared previously published small miRNA and long mRNA of a set of GC B cells and eBL tumors. MiRWalk2.0 was used to identify the validated target genes for the deregulated miRNAs, which would be important for understanding the regulatory networks associated with eBL development.

resultsWe found 211 differentially expressed (DE) genes (79 upregulated and 132 downregulated) and 49 DE miRNAs (22 up-regulated and 27 down-regulated). Gene Set enrichment analysis identified the enrichment of a set of MYC regulated genes. Network propagation-based method and correlated miRNA-mRNA expression analysis identified dysregulated miRNAs, including miR-17~95 cluster members and their target genes, which have diverse oncogenic properties to be critical to eBL lymphomagenesis. Central to all these findings, we observed the downregulation of ATM and NLK genes, which represent important regulators in response to DNA damage in eBL tumor cells. These tumor suppressors were targeted by multiple upregulated miRNAs (miR-19b-3p, miR-26a-5p, miR-30b-5p, miR-92a-5p and miR-27b-3p) which could account for their aberrant expression in eBL.

conclusionCombined loss of p53 induction and function due to miRNA-mediated regulation of ATM and NLK, together with the upregulation of TFAP4, may be a central role for human miRNAs in eBL oncogenesis. This facilitates survival of eBL tumor cells with the IGH/MYC chromosomal translocation and promotes MYC-induced cell cycle progression, initiating eBL lymphomagenesis. This characterization of miRNA-mRNA interactions in eBL relative to GC B cells provides new insights on miRNA-mediated transcript regulation in eBL, which are potentially useful for new improved therapeutic strategies.

Indexed as

Gene Expression Regulation, NeoplasticBurkitt LymphomaCell Transformation, NeoplasticChildChild, PreschoolComputational BiologyFemaleGene Expression ProfilingHigh-Throughput Nucleotide SequencingHumansMaleMicroRNAsModels, BiologicalRNA InterferenceRNA, MessengerSignal TransductionMicroRNAsRNA, MessengerEndemic Burkitt lymphomaLymphomagenesismiRNAmRNARNA sequencing

Identifiers

PMID29132323
PMCPMC5683570
OpenAlexW2769754782

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.